Objective To determine the association between SpO 2 at 5 min and preterm infant outcomes. Design Data from 768 infants <32 weeks gestation from 8 randomised controlled trials (RCTs) of lower (≤0.3) versus higher (≥0.6) initial inspiratory fractions of oxygen (FiO 2 ) for resuscitation, were examined. was associated with lower heart rates (mean difference −8.37, 95% CI −15.73 to -1.01, *p<0.05) and after accounting for confounders, with IVH (OR 2.04, 95% CI 1.01 to 4.11, p<0.05). Bradycardia (heart rate <100 bpm) at 5 min increased risk of death (OR 4.57, 95% CI 1.62 to 13.98, p<0.05). Taking into account confounders including gestation, birth weight and 5 min bradycardia, risk of death was significantly increased with time taken to reach SpO 2 80%. Conclusion Not reaching SpO 2 80% at 5 min is associated with adverse outcomes, including IVH. Whether this is because of infant illness or the amount of oxygen that is administered during stabilisation is uncertain and needs to be examined in randomised trials
AbsTrACT
Objective To determine the association between SpO 2 at 5 min and preterm infant outcomes. Design Data from 768 infants <32 weeks gestation from 8 randomised controlled trials (RCTs) of lower (≤0.3) versus higher (≥0.6) initial inspiratory fractions of oxygen (FiO 2 ) for resuscitation, were examined. setting Individual patient analysis of 8 RCTs Interventions Lower (≤0.3) versus higher (≥0.6) oxygen resuscitation strategies targeted to specific predefined SpO 2 before 10 min of age. Patients Infants <32 weeks gestation. was associated with lower heart rates (mean difference −8.37, 95% CI −15.73 to -1.01, *p<0.05) and after accounting for confounders, with IVH (OR 2.04, 95% CI 1.01 to 4.11, p<0.05). Bradycardia (heart rate <100 bpm) at 5 min increased risk of death (OR 4.57, 95% CI 1.62 to 13.98, p<0.05). Taking into account confounders including gestation, birth weight and 5 min bradycardia, risk of death was significantly increased with time taken to reach SpO 2 80%. Conclusion Not reaching SpO 2 80% at 5 min is associated with adverse outcomes, including IVH. Whether this is because of infant illness or the amount of oxygen that is administered during stabilisation is uncertain and needs to be examined in randomised trials
Main outcome measures

InTrODuCTIOn
Preductal pulse oximetry (SpO 2 ) monitoring is now an integral component of delivery room stabilisation of sick newborn infants.
1 SpO 2 is used to guide administration of fractional inspired oxygen (FiO 2 ) to achieve SpO 2 levels derived from healthy, spontaneously breathing full-term infants. 2 This is a relatively new practice. Prior to 2005, pure oxygen (FiO 2 1.0) was used for respiratory support of all newborn infants, regardless of gestation and SpO 2 was not consistently monitored. 3 Most delivery rooms, even in high resource countries, were not equipped to either blend oxygen or monitor SpO 2 . 4 In the 1990s, the Resair studies demonstrated that air (FiO 2 0.21) could be used instead of FiO 2 1.0 for resuscitating hypoxic, mature infants. 5 6 Using air, in fact, decreased oxidative stress, organ injury, 7 death 8 and encephalopathy. 9 Major changes in the use of oxygen for newborn infant stabilisation subsequently ensued. Expert committees first suggested in 2005 that air could 10 or should 11 be used to resuscitate full-term infants. With the acquisition of transitioning SpO 2 data several years later from healthy term 2 and preterm 12 infants, guidelines then recommended that FiO 2 should be, first, initiated at low levels (air for term infants and 'judicious' amounts for preterm infants) to prevent rapid rise of SpO 2 and second, FiO 2 should be adjusted to meet healthy term infant SpO 2 thresholds. 2 12 These SpO 2 recommendations were mostly applied to all infants, regardless of gestation. 13 14 However, the implications of these recommended SpO 2 thresholds on preterm infant outcomes are unknown and this is consistently acknowledged as one of the biggest knowledge gaps in clinical care of the sick preterm infant. 1 15-17 Prematurity is associated with both respiratory immaturity and anti-oxidant deficiency 18 that makes 'optimum' oxygen requirements difficult to balance. Using just air may cause hypoxaemia but conversely, using only FiO 2 1.0 will rapidly cause hyperoxaemia.
19
What is already known on this topic? ► Clinicians initiate preterm infant resuscitation with low levels of blended oxygen (FiO 2 <0.4) that is manipulated to meet SpO 2 derived from healthy term and preterm infants. ► This is now almost standard practice but whether clinicians are able to achieve recommended SpO 2 targets is unknown.
What this study adds?
► Almost half of preterm infants enrolled in oxygen titration studies did not reach SpO 2 80% at 5 min, and this was associated with increased risk of major intraventricular haemorrhage and bradycardia (heart rate <100 bpm). ► Bradycardia at 5 min increased risk of death by almost five times, suggesting that randomised trials to determine the consequences of oxygen titration and SpO 2 targeting strategies in preterm infants are urgently needed.
Original article
Escrig et al first demonstrated that resuscitation with low levels of blended oxygen (eg, FiO 2 0.3) was feasible. 20 Vento et al then showed that this decreased biochemical oxidative stress when compared with the use of higher oxygen (eg, FiO 2 0.6). 21 In 2015, international committees that lower FiO 2 (≤0.3%) should be used for preterm resuscitation and that higher oxygen levels >0.65 should be avoided. [15] [16] [17] Over the last 10 years, a paradigm shift in the use of oxygen has evolved. In 2008, 50% of Australian and New Zealand perinatal centres used FiO 2 1.0 to resuscitate preterm infants. 4 In 2015, a survey of 630 clinicians from 25 countries found that only four clinicians would use FiO 2 1.0 and >70% would use FiO 2 <0.4. Furthermore, most would target SpO 2 thresholds of 'healthy term infants' or those at the lower percentiles of healthy preterm infants. 22 Prospective acquisition of oxygen data from randomised controlled trials (RCTs) would take many years. Eight existing studies have been conducted to determine outcomes of preterm infants after resuscitation with either lower (<0.3) or higher (>0.6) initial FiO 2 . A meta-analysis of this studies showed that FiO 2 did not influence death, major intraventricular haemorrhage (IVH) or bronchopulmonary dysplasia (BPD), 23 but the association between SpO 2 and outcomes have not been examined even though the Resair 2 study showed >20 years ago that failure to achieve a 1 min SpO 2 of 60% markedly increased the risk of death in asphyxiated term infants (OR 8.6). 24 In this study, therefore, we obtained individual patient SpO 2 data from the eight RCTs 20 21 25-30 that have previously examined outcomes of premature infants <32 weeks gestation to compare outcomes of higher (≥0.6) versus lower (≤0.3) FiO 2 resuscitation strategies. We hypothesised that infants not reaching SpO 2 80% by 5 min would be at an increased risk of adverse outcomes, including death, major IVH or BPD, regardless of the initial level of FiO 2 . Original article
METhODs
Individual patient data were obtained directly from the authors of eight RCTs that initiated delivery room resuscitation with higher (≥0.6) and lower (<0.3) FiO 2 in infants <32 weeks gestation. 20 21 25-30 Four studies were excluded: authors uncontactable (1), 31 FiO 2 not titrated at birth (3). [32] [33] [34] No study examined FiO 2 between 0.31 and 0.59 (see table 1 were searched from 1990 to 1 November 2016 using the index terms: preterm/resuscitation/oxygen. Reference lists of relevant articles were also scrutinised. Data were extracted and based on consensus between at least two investigators to resolve uncertainties. Studies published in abstract and full manuscript forms were included. Each study was crosschecked for duplication.
sPO 2 TArGETs
Three studies used oximeter downloads to obtain or to verify SpO 2 data [25] [26] [27] and the rest obtained data manually. SpO 2 targets were different for each study as were FiO 2 titration protocols. SpO 2 at 5 min was used as the primary outcome because earlier readings were not consistent. SpO 2 above or below 80% (lower limit of the most common expert committee 5 min SpO 2 recommendation (80%-85%) 13 was used as a dichotomous variable to determine influence on the primary outcomes of death before hospital discharge, major IVH (≥grade 3) 35 and BPD (defined as the need for respiratory support or supplemental oxygen at 36 weeks postconceptional age). 36 
sTATIsTICAl AnAlysIs
Random effects models were used to account for variation within and between studies (heterogeneity) and to compute summary OR, mean differences (MD) and 95% CIs for dichotomous and continuous variables, where appropriate. 37 38 Heterogeneity between studies was evaluated with I 2 statistics. 39 Publication bias was assessed with Egger's test 40 41 and by funnel plot inspection. Categorical data were examined by the χ 2 test for proportions and expressed as number (%) and OR (95% CI). Parametric continuous data were examined with the two-sided Student's t-test. Logistic regression analysis using factors associated with death, IVH and BPD, including gestation, birth weight, gender, FiO 2 , low heart rate (<100 bpm) were conducted to determine the influence of 5 min SpO 2 </>80% on the primary outcomes. [42] [43] [44] Cox regression analyses was used to determine HR to estimate the effect size of confounders between time to reach SpO 2 80% and death in infants with and without bradycardia (heart rate >100 bpm) at 5 min, using model predictors of: gestation, birth weight, male gender, 5 min heart rate <100 bpm, starting FiO 2 and mean SpO 2 at 5 min.
Analyses were performed with RevMan, V.5 and SPSS (IBM) V.22. A p value of <0.05 was considered to be statistically significant.
Ethics board approval and registration with clinical trial registries
All studies had been approved from the relevant ethics boards and were registered in approved clinical trial registries (details available from individual studies). figure 2A) , took longer to reach SpO 2 ≥80% (MD 1.00, 95% CI 0.15 to 1.84), I
2 90%, p=0.02, figure 2B ) and had significantly lower SpO 2 at 5 min (MD −7.61, 95% CI −13.26 to -1.26, I
2 =89%, p=0.008, figure 2C ) than babies given higher oxygen.
Characteristics of infants with spO 2 below and above 80% at 5 min
Infants with SpO 2 <80% at 5 min were more premature and had lower birth weights than infants with SpO 2 >80%. They were also more likely to be given initial FiO 2 <0.3 (OR 3.08, 95% CI 2.26 to 4.19). There was no difference in FiO 2 administered at 5 min but mean SpO 2 (63.7% vs 91.8%) and heart rates (142.0 vs 148.7 bpm) were significantly lower in infants with SpO 2 <80%. Only two infants with SpO 2 >80% were bradycardic at 5 min (see table 3 ). figure 3A ) and that babies with SpO 2 <80% had significantly lower heart rates than those with higher SpO 2 (MD −8.37, 95% CI −15.73 to -1.01, I
2 77%, p=0.03, figure 3B ). Furthermore, babies with 5 min SpO 2 <80% had an increased risk of death (OR 2.66, 95% CI 1.45 to 4.87, p=0.02, I
2 0% (figure 4A) but not IVH (figure 4B) or BPD ( figure 4C ). 
Figure 5
Cumulative risk of death with time taken to reach SpO 2 80%. Note higher risk of death in infants with heart rates <100 bpm at 5 min (also see table 5 for HRs associated with each confounder). 
Original article DIsCussIOn
In this study, we show that only 12% of preterm infants who were resuscitated with blended oxygen in eight RCTs reached the lower limit of expert committee SpO 2 (80%) at 5 min of age.
1
The implications of these recommendations on sick preterm newborn infants are unknown as they are predominantly derived from observational studies of healthy term and preterm infants. 12 Our study showed that babies who did not reach SpO 2 80% by 5 min were more premature, but also had lower heart rates. In univariate analyses, they were more likely to die before hospital discharge and to develop a major IVH. Risk of death was also increased with the time taken to attain SpO 2 80% but whether this was iatrogenic or due to inherent illness (eg, more severe respiratory pathology) cannot be determined from this study. Nevertheless, we show that the relatively new practice of using blended oxygen and targeting SpO 2 requires urgent and careful evaluation in well-designed and sufficiently large randomised studies. Clinicians now accept lower oxygenation more readily than higher, primarily because of concerns of oxidative stress 22 but again, the implications of this practice on both short-term and long-term outcomes is unknown. Boronat et al showed no difference in 2-year neurodevelopmental outcomes after resuscitation with either FiO 2 0.3 or 0.6 45 and further evaluation of this concept is warranted after results from other studies, for example, the neurodevelopmental follow-up of babies enrolled in the Tor2pido study 25 is available. It must be acknowledged, however, that outcomes of sick newborn infants are influenced by multiple factors and not only oxygenation. After accounting for confounders, low SpO 2 appeared to be important in increasing only the risk of IVH (OR 2.04) but not death (risk changed with gestation (OR 0.65), birth weight (OR 0.99) and bradycardia (OR 4.57)) or BPD (risk influenced by factors inherent to the patient, eg, gestation (OR 0.77), birth weight (OR 0.99) and male gender (OR 2.39)). Clinicians must therefore account for all these factors when stabilising preterm babies during the first critical few minutes of life. The practice of using blended FiO 2 to target SpO 2 is a relatively new method of resuscitation and definitive data about the outcomes of this practice are still being acquired. Adopting SpO 2 recommendations requires significant infrastructure changes that may be unfeasible in resource-limited regions. 46 Therefore, fall-back safety measures that do not necessitate the use of additional equipment, for example, clinical assessment and heart rate auscultation, must be evaluated to ensure best patient outcomes.
We also caution that none of the RCTs was designed to examine infant outcomes in relation to target SpO 2 . All but two studies 29 30 were designed before the first recommended SpO 2 targets were published in 2010. 1 14 To date, there continues to be wide variability in SpO 2 recommendations. No international expert committee differentiates between term and preterm infants for SpO 2 recommendations and SpO 2 recommendations may vary by >20% between countries. 47 Further study to evaluate patient outcomes against differing SpO 2 targets is, as mentioned, greatly needed, considering the now almost ubiquitous nature of oxygen blending.
Currently, the only certain data point for oxygen administration during resuscitation is starting FiO 2 . International expert committees recommend not using FiO 2 >0.65 and to use lower FiO 2 (0.21-0.3) to initiate preterm resuscitation. 17 Note that no study has examined outcomes for initiation of resuscitation with FiO 2 0.4-0.58 or the impact of differing oxygen titration strategies. Pooled data from this study, however, shows that babies given lower (FiO 2 <0.3) were more likely to have SpO 2 <80% (OR 2.63) and lower SpO 2 (MD −7.61) at 5 min and also need 1 min more to reach SpO 2 80% after birth. Lower SpO 2 was associated with lower heart rates which in turn increased the risk of death (OR 4.57), even after accounting for gestation and birth weight differences.
Whether infants were unable to reach threshold SpO 2 because of insufficient oxygen or illness cannot be determined by this study. Certainly, there was no difference in 5 min FiO 2 in infants with SpO 2 above or below 80% or in the starting FiO 2 level between babies with and without adverse outcomes after adjustment of confounders. There is increasing evidence that premature infants may be more susceptible to poor short-term outcomes with lower oxygenation strategies. Rabi et al showed that extremely preterm infants were at increased risk of death or neurological injury after Canadian resuscitation policies were changed from FiO 2 1.0 to titrated oxygen. 48 In an unplanned, post hoc analysis, the recently closed To2rpido study showed a marginally statistically significant increased risk of death (OR 3.9, p=0.01) in babies <28 weeks gestation after initiation of resuscitation with air instead of FiO 2 1.0. 25 Whether these strategies impact on long-term (including neurodevelopmental) outcomes are unclear and need evaluation.
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